Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04150042
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:32.510067+00:00
Published At
2026-01-29T00:00:00+00:00
Record Updated At
2026-01-29
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Pancreatic Adenocarcinoma Metastatic", "BRCA1 Mutation", "BRCA2 Mutation", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma", "Breast Cancer Metastatic", "Breast Cancer Stage IV", "Pancreatic Cancer Stage IV", "HER2-negative Breast Cancer", "HER2 Negative Breast Carcinoma", "Adenocarcinoma of the Breast", "PALB2 Gene Mutation", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Pancreas Cancer", "Stage IV Pancreatic Cancer", "Stage 4 Pancreatic Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-29"
protocolSection.identificationModule.nctId
"NCT04150042"
protocolSection.identificationModule.officialTitle
"SHARON: Study of Metastatic Cancers in Patients Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Pancreatic Adenocarcinoma Metastatic (protocolSection.conditionsModule.conditions)
  • BRCA1 Mutation (protocolSection.conditionsModule.conditions)
  • BRCA2 Mutation (protocolSection.conditionsModule.conditions)
  • Pancreatic Acinar Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Breast Cancer Metastatic (protocolSection.conditionsModule.conditions)
  • Breast Cancer Stage IV (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer Stage IV (protocolSection.conditionsModule.conditions)
  • HER2-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2 Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma of the Breast (protocolSection.conditionsModule.conditions)
  • PALB2 Gene Mutation (protocolSection.conditionsModule.conditions)
  • Pancreas Cancer, Metastatic (protocolSection.conditionsModule.conditions)
  • Pancreas Cancer, Recurrent (protocolSection.conditionsModule.conditions)
  • Pancreas Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Stage 4 Pancreatic Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.